Squamous cell neoplasm

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This study tested whether an education program helps low-income, uninsured adults aged 18-45 accept and complete a free HPV vaccine series. The goal is to prevent HPV-related cancers. About 100 participants took part, and researchers tracked how many started and finished the vacc…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This study tests whether a daily dose of Taiwanese Green Propolis, a natural bee-derived supplement, can improve blood fat levels, reduce fatigue, and enhance quality of life in people who have completed treatment for oral cavity cancer. Participants take either propolis capsules…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study compares two treatment approaches for people with operable head and neck squamous cell carcinoma. One group receives low-dose radiotherapy plus targeted therapy and immunotherapy before surgery, while the other gets only targeted therapy and immunotherapy. The goal is …

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and re…

This early-stage trial tested a DNA vaccine called NWRD08 in 9 women with high-grade cervical lesions caused by HPV types 16 or 18. The vaccine was given as a shot followed by a mild electrical pulse to help cells take it up. The main goal was to check safety and see if the vacci…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This pilot study tested whether memantine, a drug used for dementia in adults, could help prevent memory and thinking problems in children receiving brain radiation for tumors like glioma or craniopharyngioma. 41 children aged 6-21 took either memantine or a placebo during radiat…

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…

This phase 3 study tested whether adding the immunotherapy drug retifanlimab (INCMGA00012) to standard platinum-based chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 583 patients who had not received prior treatment for metastati…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This phase 2 trial tests a combination of two drugs—cetuximab and dalpicilib—in people with a type of head and neck cancer that has returned or spread and no longer responds to standard immunotherapy. The study includes 28 adults aged 18 to 75 whose tumors are HPV-negative. The g…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This study looked at when to start giving a drug called rhTPO to cervical cancer patients whose platelet levels drop during chemoradiation. The goal was to see if starting treatment earlier could prevent severe low platelet counts. Researchers studied 75 patients and compared two…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This phase 2 study tested a combination of the drug Tarceva (erlotinib) with RADPLAT (radiation and intra-arterial cisplatin) in 21 patients with advanced head and neck cancer. The goal was to see if the combination was safe and effective at shrinking tumors. Researchers measured…

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This early-stage trial tested a combination of two oral drugs, tipifarnib and alpelisib, in 45 adults with recurrent or metastatic head and neck squamous cell carcinoma that has specific genetic changes (HRAS overexpression or PIK3CA mutations). The goal was to find a safe dose a…

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…

This study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…

This phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …

This early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…

This study tested whether adding an experimental drug called LBL-007 to standard immunotherapy and chemotherapy helps shrink tumors better in people with advanced esophageal cancer that cannot be surgically removed. About 118 participants received either the three-drug combo or t…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase 2 trial tested two chemotherapy drugs, paclitaxel and carboplatin, given before surgery to 79 people with locally advanced head and neck cancer. The goal was to see how well the drugs shrink tumors before surgery. The main measure was a major pathologic response, meani…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This study tested whether exenatide, a diabetes drug, plus lifestyle changes helps adults with severe weight gain after treatment for a rare brain tumor (craniopharyngioma). 42 adults aged 18-75 took either exenatide or a placebo for 6 months. The main goal was to see if they los…

This early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared givi…

This study tested whether a lower dose of radiation therapy, with or without the chemotherapy drug cisplatin, can effectively treat advanced oropharyngeal (throat) cancer in patients who are non-smokers. The trial enrolled 316 people with p16-positive cancer, a type linked to HPV…

This study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …

This early-stage trial tested the safety of adding olaparib to standard chemotherapy and radiation for people with advanced head and neck cancer. Sixteen patients took part to find the best dose and see how well they tolerated the combination. The goal was to control the disease,…

This early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…

This study looked at whether adding cetuximab to avelumab works better than avelumab alone for people with advanced head and neck cancer that has come back or spread. The cancer in these patients is not curable, and average survival is less than a year. The trial first checked th…

This phase 2 trial tested a new approach for people with intermediate-risk HPV-related head and neck cancer. Participants received an HPV-16 vaccine (ISA101b) plus the immunotherapy drug pembrolizumab alongside standard chemoradiation. The goal was to see if this combination coul…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This study tested whether giving the immunotherapy drug pembrolizumab for one year after standard treatment could help prevent head and neck cancer from coming back in 100 patients at high risk for recurrence. Participants received either pembrolizumab or a placebo. The main goal…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a combination of two drugs, ramucirumab and pembrolizumab, in 43 people with head and neck cancer that had spread or come back. The goal was to first find a safe dose and then see if the combination could shrink tumors. The approach aims to block blood vessel gr…

This study tested whether a combination of two chemotherapy drugs, gemcitabine and cisplatin, can shrink tumors in people with advanced or metastatic penile cancer. Fifty adults with inoperable or spreading disease took part. The main goal was to see how many patients responded t…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a new surgical technique for esophageal cancer that avoids a large chest incision. 35 patients with early-stage cancer received this less invasive procedure. The goal was to see if it could lower complication rates while still effectively removing the cancer. Re…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This study tested a combination of two drugs, niraparib and dostarlimab, in 10 people with head and neck cancer that had come back or spread. The goal was to see if the combination could shrink tumors or slow the cancer. Participants had to be able to swallow pills and have no ot…

This phase 2 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard surgery, radiation, and chemotherapy could help prevent head and neck cancer from coming back. The study enrolled 67 adults with advanced, surgically removable head and neck squam…

This early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…

This study tested a DNA-based vaccine called VGX-3100 in 44 HIV-positive adults with high-grade anal precancer caused by HPV types 16 or 18. The vaccine was given with a mild electric pulse (electroporation) to help cells absorb it and boost the immune system's attack on the abno…

This phase 2 trial tested whether adding tiragolumab to atezolizumab (Tecentriq) helps shrink tumors better than atezolizumab alone in people with advanced head and neck cancer that has come back or spread. The study enrolled 123 adults whose tumors have a specific protein (PD-L1…

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…

This study tested the drug nivolumab (Opdivo) in 39 people with head and neck cancer who had already received radiation and then had a second surgery to remove remaining cancer. The goal was to see if nivolumab could help prevent the cancer from coming back and to check for side …

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This phase 3 trial tested whether adding lenvatinib (Lenvima) to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with recurrent or metastatic head and neck squamous cell carcinoma. The study enrolled 511 participants whose tumors express PD-L1. Researche…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested whether giving fewer, higher-dose radiation sessions after surgery for head and neck cancer is safe. Eighteen adults with certain risk factors received one of three shortened radiation schedules. The goal was to find the shortest course that does not cause sever…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 33 adults with advanced head and neck cancer that had worsened after chemotherapy. The goal was to see if the combo could shrink tumors or slow disease progression. Results may help guide future treatm…

This study tested a treatment plan for people with advanced head and neck cancer that cannot be removed by surgery. The plan combined the immunotherapy drug camrelizumab with chemotherapy and radiation. 39 adults took part. The goal was to see if the treatment could help control …

This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Resea…

This study tested whether giving less intense treatment after surgery for HPV-related throat cancer can reduce side effects like weight loss and the need for a feeding tube. 63 patients had surgery and then received either lower-dose radiation or no radiation, depending on their …

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…

This study looked at whether removing small, early-stage anal cancers with local surgery alone is safe and effective for people with HIV. The goal was to see if this less invasive approach could avoid the need for stronger treatments like radiation or chemotherapy. Sixteen partic…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a sa…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study me…

This phase 3 trial tested whether adding two immunotherapy drugs, atezolizumab and tiragolumab, to standard chemotherapy could help people with advanced esophageal cancer live longer. About 461 participants received either the immunotherapy combo plus chemo or a placebo plus chem…

This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…

This study tested a new drug called TAK-676, alone and with pembrolizumab, in 248 adults with advanced solid tumors that had no standard treatment options. The main goal was to check safety and find the highest dose that causes few side effects. The study also looked at how well …

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This phase 2 trial tested a combination of three drugs—camrelizumab (an immunotherapy), cetuximab (a targeted therapy), and chemotherapy—as a first treatment for people with head and neck cancer that has come back or spread. The study enrolled 41 participants and measured how man…

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This study tested whether combining two FDA-approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. A total of 95 participants received the drug combination to find the best dose and see if it improves surv…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This phase 2 trial tested two experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had worsened after chemotherapy. The drugs are bispecific antibodies designed to block two immune checkpo…

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This early pilot study tested a new radioactive bandage called CivaDerm on 10 people with common skin cancers (basal cell or squamous cell carcinoma). The bandage delivers radiation directly to the skin surface, aiming to destroy cancer cells while sparing healthy tissue. The stu…

This study tested a blend of six Chinese herbs, called Anti-tumor B, in 30 people with squamous cell cancer of the mouth. The goal was to see if the herbs could slow cancer cell growth before standard treatment. Results focused on changes in a cell growth marker called Ki-67.

This early-stage study tested the safety of adding the drug afatinib to standard radiation therapy for people with head and neck cancer at risk of recurrence. Afatinib blocks proteins that help cancer grow and may make cancer cells more sensitive to radiation. The study included …

This study tested whether giving lower doses of radiation after surgery for head and neck cancer could reduce long-term side effects like dry mouth and trouble swallowing, while still keeping the cancer from coming back. About 200 patients with certain stages of oral, throat, or …

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a three-step treatment for head and neck cancer that uses chemotherapy before surgery, then adjusts further treatment based on risk. The goal was to see if this personalized approach could reduce side effects while still controlling the cancer. 40 adults with a …

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This Phase 3 trial tested whether adding lenvatinib to pembrolizumab (Keytruda) helps people with recurrent or metastatic head and neck squamous cell carcinoma that has a specific marker (PD-L1). The study enrolled 112 participants and compared the combination against pembrolizum…

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This phase II trial tested whether adding sorafenib to cetuximab works better than cetuximab alone for patients with advanced head and neck cancer that has come back or spread. Fifty-five adults with various types of head and neck cancer took part. The study measured how long pat…

This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent skin cancer from returning in people with high-risk locally advanced squamous cell carcinoma who had already undergone surgery and radiation. About 450 participants were randomly assigned…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This study tested whether adding the immunotherapy drug pembrolizumab after standard chemoradiotherapy and surgery could prevent cancer recurrence in 26 patients with high-risk esophageal squamous cell carcinoma. Participants received cisplatin-based chemoradiotherapy followed by…

This early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This phase 2 trial tested whether giving an extra dose of radiation to the most resistant parts of a tumor, identified by a special MRI scan (DCE-MRI), could improve outcomes for people with advanced head and neck cancer. 106 participants received standard chemoradiation (cisplat…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This phase 3 trial tested whether adding a targeted antibody (cetuximab) to standard chemotherapy (cisplatin) helps people with advanced head and neck cancer that has spread or come back. About 120 patients received either cisplatin plus cetuximab or cisplatin plus a placebo. The…

This Phase 1 trial compared a new biosimilar drug, RPH-002, to the standard cancer drug Erbitux in 118 patients with advanced head and neck cancer that could not be removed by surgery. The main goals were to see if RPH-002 reaches similar levels in the blood and has a similar saf…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This small early-phase trial tested an experimental drug called rigosertib in just 2 people with a rare blistering skin disease (recessive dystrophic epidermolysis bullosa) who also had advanced skin cancer. The goal was to see if the drug could shrink tumors and whether it was s…

This study tested whether adding the drug olaparib to standard treatment (pembrolizumab plus chemotherapy) helps people with advanced squamous non-small cell lung cancer live longer or keep the cancer from growing. About 850 adults who had not been treated before took part. The g…

This phase 3 trial tested whether adding the drug olaparib (Lynparza) to standard treatment with pembrolizumab (Keytruda) and chemotherapy helps people with advanced nonsquamous lung cancer live longer without their disease worsening. Over 1,000 participants received either olapa…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This phase 2 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and radiation after surgery could help prevent cancer from returning in people with advanced head and neck cancer. The study enrolled 211 patients who had their tumor…

This phase 2 trial tested whether adding an experimental drug called AZD1775 to standard chemotherapy (carboplatin and paclitaxel) could help people with advanced squamous cell lung cancer. The study enrolled 42 participants and measured how long they lived without their cancer g…

This phase 3 trial tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced esophageal cancer live longer or keep their cancer from growing. About 970 participants with inoperable or metastatic esophageal squamous ce…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …

This study tested a new way to give radiation for head and neck cancer. Instead of treating the whole neck, doctors used artificial intelligence to focus radiation only on the cancer spots. 67 patients took part to see if this approach could reduce side effects without increasing…

This study looked at whether using an anti-cancer cream (5-fluorouracil) in the vagina after surgery is an acceptable and feasible way to treat cervical precancer in 180 South African women living with HIV. The goal was to see if women would stick with the treatment and find it a…

This early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…

This study tested combinations of the immunotherapy drug durvalumab with other drugs (danvatirsen, AZD5069, or tremelimumab) in 340 adults with advanced solid tumors or head and neck cancer. The goal was to find safe doses and see if the combinations shrink tumors. The trial has …

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…

This study tested a treatment for people with HPV-related throat cancer. It combined a higher dose of radiation with the chemotherapy drug docetaxel. The goal was to see if this approach could better control the tumor and improve survival. The study involved 81 participants and w…

This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…

This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation helps people with locally advanced head and neck cancer live longer without the disease getting worse. Over 800 participants received either pembrolizumab plu…

This phase 2 trial tested a combination of two targeted drugs, afatinib and cetuximab, in 50 patients with advanced head and neck cancer that had spread or come back. All participants had already tried standard treatments like chemotherapy or immunotherapy. The main goal was to s…

This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…

This study tested a shorter radiation schedule (3 weeks instead of 6-7) for head and neck cancer in people aged 70 and older. The goal was to see if it could still control the cancer while reducing side effects and treatment gaps. 37 participants received either adjuvant or defin…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had returned or spread. The goal was to see if the combination could shrink tumors or slow the disease. Participants were grouped based on whether they …

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study looked at whether the HPV vaccine can help prevent high-grade cervical lesions (precancerous growths) in women living with HIV who were already being treated for HPV. About 536 women took part, receiving either the HPV vaccine or a placebo. The goal was to see if the v…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study looked at 120 people with esophageal cancer who had a type of surgery called McKeown esophagectomy. Half had the right gastric artery preserved, and half had it tied off. The goal was to see if preserving the artery lowers the chance of leaks or narrowing where the new…

This trial tested a new treatment for people with Epstein-Barr virus (EBV)-positive head and neck cancer that has spread or come back. The treatment uses specially engineered immune cells (TCR-T cells) that recognize EBV on cancer cells and also release a PD1 blocker to help them…

This study tested whether adding the immunotherapy drug nivolumab to standard radiation and chemotherapy can help prevent cancer from returning in people with high-risk HPV-related throat cancer. The trial enrolled 26 participants with advanced-stage disease. Researchers measured…

This pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …

This early-phase study tested a new drug called CUE-101, alone or with pembrolizumab, in 80 adults with HPV16-positive head and neck cancer that had spread or returned. The main goals were to check safety and find the right dose. Researchers also looked at whether the drug helped…

This early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…

This early study tested a drug called cemiplimab, which helps the immune system attack cancer cells. The drug was injected directly into skin tumors (squamous cell or basal cell carcinoma) for 3 to 12 weeks before planned surgery. The main goal was to check safety and find the ri…

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This study looked at whether giving radiation therapy after surgery can prevent early-stage oral cancer from coming back. It included 392 patients with tumors at least 5mm thick. Half received radiation, half were just watched. The main goal was to see if radiation reduced local …

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

This Phase 3 trial tested whether the oral drug afatinib works better than the standard injected drug methotrexate for people with advanced head and neck cancer that has worsened after platinum chemotherapy. The study enrolled 340 patients and measured how long they lived without…

This early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.

This large phase 3 trial studied nearly 1,000 people with HPV-related oropharyngeal cancer to see if replacing chemotherapy with a targeted drug (cetuximab) during radiation could work as well or better. The goal was to find a treatment that controls the disease while possibly re…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This phase II trial tested a personalized approach for people with advanced head and neck cancer that had stopped responding to prior immunotherapy. Researchers used genetic testing to choose which drug to add to nivolumab—either relatlimab or ipilimumab. The study enrolled 20 pa…

This early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…

This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…

This study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.

This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…

This early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This study tested a new device that delivers targeted radiation to early-stage basal and squamous cell skin cancers. Thirty-six people aged 60 and older received treatment, and researchers tracked how well the cancer was controlled, cosmetic results, and quality of life. The goal…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This early-phase study tested a combination of low-dose radiation, an immunotherapy drug (tislelizumab), and a targeted therapy (afatinib) given before surgery to people with head and neck cancer. The main goal was to find a safe dose and see how well the treatment shrinks tumors…

This early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study looked at kidney transplant patients who already had one skin cancer. It compared switching their anti-rejection medicine to rapamycin versus staying on standard drugs. The goal was to see if rapamycin could prevent new skin cancers over two years while keeping the tra…

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.

This study tested giving the drug cemiplimab before surgery to people with advanced skin cancer (stage II to IV). The goal was to see if the drug could shrink or eliminate the tumor before the operation. 79 adults took part. The main focus was on how many patients had no cancer c…

This study tested whether the drug everolimus can reduce new skin cancers in heart transplant patients who already had skin cancer. 175 participants received either everolimus or standard immunosuppressants. The goal was to see if everolimus lowers the number of new skin tumors n…

This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …

This early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This early-phase study tested a shorter, more intense radiation schedule (completed in 3 weeks instead of the usual 6) combined with chemotherapy for people with HPV-related throat cancer. The goal was to find the safest dose that still controls the cancer. Only 24 patients took …

This phase 2 trial tested whether adding eftilagimod alpha to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that cannot be removed by surgery. The study included 171 participants whose tumors had certain marker…

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This early-phase trial tested a combination of two drugs — IRX-2 and durvalumab — in 19 people with advanced head and neck cancer that could not be cured by standard treatments. The goal was to see if the combination was safe and could boost the immune response inside tumors. The…

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This study tested whether adding an experimental drug (epacadostat) to an immunotherapy (pembrolizumab) works better than standard chemotherapy for people with advanced head and neck cancer that has come back or spread. 89 adults took part. The main goal was to see how many patie…

This study tested whether a second round of treatment with tiny radioactive seeds (DaRT) could safely shrink or control skin, mouth, or soft tissue cancers that came back after the first treatment. Only 2 people took part, and researchers measured tumor response and side effects.…

This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people with head and neck cancer that has returned or spread and is no longer responding to standard treatments. About 408 participants were randomly assigned to receive the combination…

This phase 2 trial tested whether adding the immunotherapy drug tislelizumab to chemotherapy and/or radiation before surgery could help completely eliminate esophageal cancer in 70 patients. The goal was to see if the tumor and all cancer cells in lymph nodes were gone at the tim…

This phase 2 study tested whether adding the drug erlotinib to standard chemotherapy (docetaxel plus cisplatin or carboplatin) helps shrink head and neck tumors before surgery. 55 patients with advanced but operable head and neck cancer took part. The main goal was to see how man…

This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side …

This early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.

This study looked at 65 people with advanced head and neck cancer that had spread to lymph nodes. It compared two approaches: having surgery to remove affected lymph nodes before chemo-radiation, versus chemo-radiation alone. The goal was to see if upfront surgery could reduce tr…

This early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…

This study looked at 200 people with advanced esophageal cancer to compare two treatments before surgery: immunotherapy combined with chemotherapy, versus chemotherapy plus radiation. Both treatments led to similar long-term survival rates. The immunotherapy combo may offer extra…

This Phase 2 trial tested whether adding the immunotherapy drug durvalumab to standard chemoradiation (FOLFOX and radiation) helps patients with unresectable esophageal cancer. 112 patients were randomly assigned to receive either chemoradiation alone or chemoradiation plus durva…

This phase 2 trial tested a combination of a short, intense course of radiation (quad-shot) and the immunotherapy drug pembrolizumab in 21 people with advanced, recurrent, or metastatic head and neck cancer. The goal was to see if the combination could shrink tumors and be safe. …

This phase 2 trial tested the chemotherapy drug mitomycin C in 48 patients with incurable head and neck cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. Researchers hope to find a new option for patients with very lim…

This study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested a new way of giving radiation to people with head and neck cancer. The goal was to lower the radiation dose to healthy neck areas to reduce side effects like trouble eating, while still keeping the cancer from coming back. About 300 patients took part, and the r…

This study tested whether adding the drug buparlisib to standard chemotherapy (paclitaxel) helps people with advanced head and neck cancer live longer. About 487 adults whose cancer had returned or spread and who had already tried other treatments took part. The goal was to see i…

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This early-phase trial tested whether adding the immunotherapy drug atezolizumab before and during standard chemoradiation could help control advanced cervical cancer that has spread to lymph nodes. Forty participants received the combination to see if it activated the immune sys…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This study tested the drug nivolumab in 17 people with advanced oral cavity cancer before they had surgery. The goal was to see if the drug could shrink tumors before removal. Nivolumab is an immunotherapy that helps the immune system fight cancer. The trial has been completed.

This early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…

This Phase 3 trial tested whether adding the immunotherapy drug retifanlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced anal cancer that cannot be removed by surgery. The study enrolled 308 adults who had not received chemotherapy for their a…

This pilot study tested whether applying prescription fluoride varnish to teeth every three months during the first year after radiation therapy for head and neck cancer can reduce cavities and gum problems. 13 adults with at least 4 natural teeth and certain cancers took part. T…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…

This study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had returned or spread and could not be cured. The goal was to see if the combination could shrink tumors or slow the disease. The approach aims to control the cance…

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …

This study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone. 18 a…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…

This study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This study tracked 287 people with advanced skin cancer (squamous cell or basal cell) to see how well the drug cemiplimab works outside of a clinical trial. Researchers measured tumor shrinkage, survival, and side effects. The goal was to understand real-world effectiveness and s…

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This phase II trial tested the drug Minnelide in 16 adults with a rare and aggressive form of pancreatic cancer called adenosquamous carcinoma of the pancreas (ASCP) that had not responded to prior treatments. Participants took Minnelide by mouth daily for 21 days of each 28-day …

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This study tested a vaccine called PepCan in 17 people who had head and neck cancer and were in remission. The goal was to see if the vaccine is safe and can reduce the chance of the cancer returning. Participants received seven injections of either PepCan or a placebo over about…

This early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe and effective for people with advanced head and neck cancer. 59 participants received pembrolizumab before, during, and after their regular treatment. The goal was…

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…

This phase II trial tested whether adding the targeted drug cetuximab to standard chemotherapy and radiation could help prevent head and neck cancer from coming back after surgery. The study enrolled 53 patients with certain high-risk features. The main goal was to see how many p…

This Phase 2 trial tested a combination of two immunotherapies—PDS0101 and pembrolizumab (Keytruda)—in 95 adults with HPV16-positive head and neck cancer that had returned or spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received b…

This study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…

This phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This study tested whether a special light (autofluorescence) can help doctors spot early signs of mouth cancer in people who smoke and drink heavily. 180 adults hospitalized for alcohol withdrawal took part. The goal was to see if the light technique is more reliable than a stand…

This study tested a new type of PET-CT scanner that can scan a tumor right after it is removed from the body. Patients with prostate or head and neck cancer received a small amount of radioactive tracer before surgery, which sticks to cancer cells. After removal, the specimen was…

This study tested a device called an 'artificial nose' that analyzes breath to detect head and neck cancer. 45 people (some with cancer, some healthy) gave breath samples. The device used sensors to create a unique breath pattern, aiming to tell who had cancer and who did not.

This study tested whether a special type of MRI (diffusion-weighted MRI) can predict if head and neck cancer will come back after chemoradiotherapy. Fifty-nine patients had two MRIs: one before treatment and one three months after. The goal was to see if changes in water movement…

This study tested a new mouthwash-based DNA test to see if it can find HPV in saliva, which might help detect HPV-related throat cancer early. Researchers compared results from 360 people — some with throat cancer and some without. The goal was to see how accurate the test is at …

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This study tested whether injecting a radioactive tracer around oropharynx tumors and using SPECT-CT scans can map lymph node drainage. Twelve patients with oropharynx cancer participated. The goal was to see if this imaging method is practical and could help guide treatment deci…

This study tested a new blood test (liquid biopsy) to see if it could find any cancer left behind after surgery in 103 people with HPV-related head and neck cancer. The goal was to catch remaining disease early, which could help doctors decide if more treatment is needed. The tes…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This trial investigates whether a low-level diode laser can prevent or reduce severe mouth sores (mucositis) caused by radiation and chemotherapy in people with advanced head and neck cancer. Participants receive either real laser therapy or a non-functional placebo laser during …

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This study tested whether quercetin, a natural substance found in some foods, could help prevent a type of mouth cancer in people with Fanconi anemia, a rare genetic condition that raises cancer risk. 48 participants took quercetin to see if it reduced certain cell changes linked…

This study tested whether a daily application of diclofenac gel, a common anti-inflammatory drug, can reverse certain biomarkers in the skin that are linked to non-melanoma skin cancer. Twenty-four adults at risk for skin cancer applied the gel for 30 days, and researchers took s…

This study looked at whether giving people personalized information about their genetic risk for melanoma could encourage them to protect themselves from the sun. Over 2,000 adults received either standard sun safety tips or tailored advice based on their DNA. Researchers then tr…

This study tested whether adding thalidomide to glutamine can delay the onset of severe mouth sores caused by radiation therapy. 138 oral cancer patients were randomly assigned to receive either the combination or glutamine alone during their radiation treatment. The main goal wa…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study tests a technique called episodic future thinking (EFT) to help smokers reduce cigarette use. Participants imagine positive events they look forward to in the next year, like a vacation or family gathering, and receive smartphone prompts. The goal is to see if focusing…

This study looked at whether a group resistance exercise program could help head and neck cancer patients maintain muscle and quality of life during chemoradiation. Twenty adults with advanced head and neck cancer took part in supervised strength training sessions. Researchers me…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This study tested a new swallowing exercise for people who have trouble swallowing after treatment for head and neck cancer. The exercise trains patients to start swallowing while breathing out, which may help prevent food or liquid from entering the airway. 88 survivors particip…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This phase 2 trial tested whether adding venlafaxine (an antidepressant) to a standard pain regimen of gabapentin, methadone, and oxycodone could better control pain in 62 people with head and neck cancer undergoing chemoradiation. The study measured pain scores and side effects …

This study tested whether having a dietitian visit patients at home during radiotherapy could improve their quality of life. 117 adults with head and neck cancer took part. The goal was to see if personalized nutrition advice helps patients cope better with treatment side effects…

This study tested whether a short exercise program before chemoradiotherapy helps head and neck cancer patients maintain physical function. 47 adults with head and neck cancer were randomly assigned to either an exercise prehabilitation group or usual care. The exercise program l…

This study tested a new type of radiation therapy that adjusts the treatment beam each day based on the patient's current anatomy. The goal was to see if this daily adaptive approach could reduce chronic dry mouth (xerostomia) compared to standard radiation in 50 people with head…

This study tested whether shining a red LED light on mouth sores caused by radiation therapy can help them heal. 28 people with head or neck cancer who already had mild sores received a 7-minute light treatment before each radiation session. The main goal was to see if the sores …

This study looked at skin problems in 57 patients with advanced head and neck cancer who received a combination of the drug cetuximab and radiation therapy. The goal was to track and understand skin side effects during treatment. Researchers also measured quality of life and tumo…

This early-phase study tested whether alpha lipoic acid, a dietary supplement, can reduce pain and side effects in people with head and neck cancer undergoing chemoradiation. Only 5 patients were enrolled to find a safe and tolerable dose. The goal was to see if it's worth studyi…

This study looked at whether head and neck cancer patients would use medical cannabis to help with side effects during chemotherapy and radiation. 30 patients were observed to see how many signed up for and obtained medical cannabis. The goal was to understand if cannabis could b…

This study looked at whether eating only during an 8-10 hour daytime window (without cutting calories) could help immunotherapy work better in people with advanced head and neck cancer. 29 patients were asked to follow this eating pattern, and researchers tracked how well they st…

This study tested whether pentoxifylline, a drug used for blood flow problems, can protect the kidneys from damage caused by cisplatin chemotherapy in head and neck cancer patients. 90 adults receiving cisplatin for the first time took part. Researchers measured kidney injury usi…

This study looked at whether a home-based exercise program can help people with head and neck cancer maintain movement, muscle strength, and posture while undergoing radiation therapy. Twenty-four adults who had surgery and were scheduled for radiation took part. The goal was to …

This study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…

This study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…

This study tested ozone therapy to treat painful mouth sores caused by radiation and chemotherapy in 58 head and neck cancer patients. Patients received professional ozone treatments at the dental clinic plus ozone-based toothpaste, mouthrinse, and gel to use at home for 15 days.…

This study tested whether using computer-based virtual planning before jaw reconstruction surgery improves patients' quality of life compared to standard surgery. 132 adults with oral or oropharyngeal cancer who needed a fibula free-flap reconstruction took part. The main goal wa…

This study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…

This study follows head and neck cancer patients who received radiation therapy to see how many teeth they lose over two years. It also looks at other mouth problems like dry mouth and bone damage. The goal is to better understand and manage these long-term side effects.

This study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…

This study enrolled 500 skin cancer patients in China and analyzed over 1.2 million of their social media posts using artificial intelligence. The goal was to see if AI could detect signs of psychological distress and suicidal thoughts. Researchers hope this approach could lead t…

This early-phase study tested very small amounts of several cancer drugs (rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab) injected directly into head and neck tumors in 17 people. The goal was to see how each drug affects the tumor's environment at the injecti…

This study examined 119 people with precancerous or early skin cancer lesions to understand how cells change as they become cancerous. Researchers took small skin samples and analyzed their metabolism and protein markers. The goal was to learn more about the transition from harml…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This completed study looked at 50 people with advanced head and neck cancer that had stopped responding to chemotherapy. Researchers gave them the drug nivolumab and analyzed their tumors and blood to find biological markers that could predict who would respond best. The goal was…

This study tested whether a defined mixture of live gut bacteria from a healthy donor (MET-4) is safe and can be detected in patients with advanced oropharyngeal cancer receiving standard chemoradiation. Thirty participants took the bacteria by mouth daily for up to four weeks. T…

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This study tested a simple photo-based method to measure changes in nose shape and size after skin cancer surgery. Researchers took before-and-after photos of 68 patients who had surgery for common skin cancers. The goal was to see if this photographic approach could be a reliabl…

This study looked at how repeatable and reproducible ADC maps are for measuring head and neck cancer in 58 adults. Participants had MRI scans using a standard method to see if results were consistent across different machines and sessions. The goal was to improve the reliability …

This study looked at whether synthetic cooling agents, which replace banned menthol in cigarettes, change how appealing or addictive cigarettes are. Researchers had 34 young adult smokers try these new cigarettes and measured their smoking behavior and preferences. The goal was t…

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study tested whether a PET scan using a tracer called FMISO can measure oxygen levels (hypoxia) in head and neck cancers. Sixteen patients received the scan before starting radiotherapy. The goal was to see if the amount of hypoxia seen on the scan could predict how well the…

This study looked at 100 healthy adults to see how tobacco and alcohol use cause genetic changes in cells lining the mouth. Researchers collected cheek cells using a gentle brush and searched for mutations linked to oral cancer. The goal was to understand how these substances mig…

This completed study used artificial intelligence to examine electronic health records from 10,000 head and neck cancer patients. The goal was to create models that can predict the risk of cancer coming back or progressing, and to identify which patients might live longer after i…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This study looked back at 387 patients with esophageal cancer to compare two chemotherapy drugs, nab-paclitaxel and paclitaxel, given before surgery. The goal was to see which drug leads to better outcomes like complete cancer removal. The study is completed, but results are not …

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…

This study looked at 41 people who had early-stage vocal cord cancer and were treated with either surgery or radiation. The goal was to see which treatment led to better voice quality five years later. Patients filled out a questionnaire about their voice, and doctors also measur…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked for the most effective and practical way to screen for anal high-grade lesions (a precancerous condition) in Thai men who have sex with men and transgender women. Researchers tested different screening methods in 950 participants to see which approach finds the …

This completed trial tested a mobile app and web platform (BD4QoL) to monitor quality of life in 410 head and neck cancer survivors after curative treatment. The goal was to see if the platform could reduce or catch early declines in quality of life compared to standard follow-up…

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affe…

This study analyzed data from 414 esophageal cancer patients who received chemoimmunotherapy before surgery. Researchers developed a new 'bio-anatomical' staging system that combines tumor characteristics and immune response to better predict survival and guide post-surgery treat…

This early-phase study looked at whether a protein from the Maackia amurensis seed (MASL) can target a receptor called podoplanin found on oral cancer and precancerous cells. Researchers measured how much of this receptor was present in tissue samples from 18 adults with suspicio…

People with achalasia, a swallowing disorder, have a much higher risk of developing esophageal cancer. This study tested whether spraying a special dye (Lugol) during an endoscopy could help doctors find early signs of cancer (dysplasia) in 39 patients who had achalasia for over …

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This completed study looked at whether circulating tumor cells (CTCs) in the blood can help predict or detect early return of oropharyngeal cancer. Researchers took blood samples from 12 patients at different times (diagnosis, after treatment, and during follow-up) and analyzed t…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study tested whether a mathematical model could help doctors choose the best radiation schedule for people with HPV-positive throat cancer. The goal was to see if personalized dosing could shrink tumors faster than standard treatment. Fifty-five adults took part, and researc…

This study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…

This completed study analyzed tumor and blood samples from 160 people with esophageal or rectal cancer. Researchers looked for genetic markers in the EGFR signaling pathway that might predict how well a patient responds to chemoradiotherapy given before surgery. The goal is to be…

This study analyzed medical records from 1197 patients in China with advanced esophageal cancer who received immunotherapy (anti-PD-1) plus chemotherapy as their first treatment. The goal was to see how long patients lived and how long the cancer stayed under control in everyday …

This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …

This study tested whether taking the drug BYL719 (Alpelisib) for 14 days before surgery could change certain biological markers in head and neck cancer tissue. Fifteen patients with resectable head and neck squamous cell cancer took the drug, and researchers compared tissue sampl…

This study tested whether a deeper self-collected swab (5 cm) collects better cell samples from the anal canal compared to a shallower one (3 cm). Fifty adults at higher risk for anal cancer participated. The goal was to see which depth gives a more useful sample for screening, w…

This study looked at how men and women react differently when they switch from regular cigarettes to a standard research e-cigarette. About 169 adult smokers took part. The goal was to understand if gender affects how much people use e-cigarettes and how dependent they become on …

This study looked at 500 children who had surgery for a rare brain tumor called craniopharyngioma. Researchers used MRI scans to grade how much the tumor damaged a key brain area (the hypothalamus). They found that more damage was linked to higher rates of growth hormone deficien…

This French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…

This study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…

This study looked at 33 people who had surgery for oral or throat cancer and received a collagen patch (Tachosil) to help rebuild the area. Researchers asked patients to fill out questionnaires about their swallowing and voice the day before surgery, and again at 1 month and 6 mo…

This study looked at how 78 patients with high-risk skin cancer on the head or neck felt about their treatment decisions, quality of life, and satisfaction with care. Researchers used standard questionnaires to measure these factors at two points: right after a team of doctors di…

This study looked at 16 people with a type of throat cancer (squamous cell carcinoma of the oropharynx). Researchers used two types of scans—PET and MRI—to measure oxygen levels inside the tumors. They also checked tumor samples under a microscope to see if the scan results match…

This study tested a personalized blood test that looks for tumor DNA in 40 patients with advanced head and neck cancer. The goal was to see if the test could help predict how the disease will progress and detect if the cancer comes back after treatment. Researchers took blood sam…

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study examined whether certain gene variations (FCGR2A and FCGR3A) influence how well the drug cetuximab works in people with advanced upper aerodigestive tract cancers that have spread or come back. Researchers analyzed blood samples from 121 participants to look for these …

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study from M.D. Anderson Cancer Center tested what happens when daily and occasional smokers use very low nicotine cigarettes along with e-cigarettes that have different nicotine levels. Researchers measured how many cigarettes people smoked, their nicotine levels, and withd…

This completed study examined 217 Hispanic people living with HIV in California, Mexico, and Puerto Rico to see if the types of bacteria in the anus are linked to high-risk HPV infection and pre-cancerous lesions. Researchers collected anal swabs and questionnaires to compare mic…

This study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…

This study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…

This completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…

This early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…

This completed study looked at how well the HPV vaccine protects against HPV infections over time in over 3,000 Rwandan women aged 18-28, some living with HIV and some without. Researchers collected blood, oral, and other samples to measure vaccine effectiveness and long-term ant…

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …

This study followed 240 people with head and neck cancer to see how their swallowing changed from diagnosis to 18 months after their first treatment. Researchers used a questionnaire called the Deglutition Handicap Index (DHI) to measure patients' own experience of swallowing pro…